Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GOG-0182: Paclitaxel/Carboplatin vs Triplets/Sequential Doublets in Ovarian Cancer
NCT00011986Phase 3Completed
- Sponsor
- GOG Foundation
- Start
- Jan 2001
- Primary completion
- Mar 2010
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gemcitabine, pegylated liposomal doxorubicin and topotecan liposome in ovarian epithelial cancer and primary peritoneal carcinoma (PPC) (5 arms), sponsored by GOG Foundation. Primary endpoints: Overall Survival up to 9 years and Progression-free Survival up to 9 years. Started Jan 2001; status: completed.
02
Drugs
gemcitabinepegylated liposomal doxorubicintopotecan liposome
03
Conditions
ovarian epithelial cancerprimary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT00011986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00011986.